Open access journal of the Ferrata-Storti Foundation, a no profit organization
Letters to the Editor

Bi 38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicities for the treatment of multiple myeloma.

Institut de recherche Saint-Louis, Inserm U976;
Institut de recherche Saint-Louis, InsermU976;
Institut de recherche Saint-Louis, Inserm U976;
Institut de recherche Saint-Louis, Inserm U976;
Institut de recherche Saint-Louis, Inserm U976;
Institut de recherche Saint-Louis, Inserm U976;
Immunology-Haematology department, Hôpital Saint-Louis, AP-HP
Institut de recherche Saint-Louis, Inserm U976;
Immunology-Haematology department, Hôpital Saint-Louis, AP-HP
Immunology-Haematology department, Hôpital Saint-Louis, AP-HP
Institut de recherche Saint-Louis, Inserm U976;
Haematologica Early view Jul 16, 2020 https://doi.org/10.3324/haematol.2019.242453

Abstract

Not available.

Figures & Tables

Article Information

Early view : Letters to the Editor
 
DOI
https://doi.org/10.3324/haematol.2019.242453
Pubmed
32675220
 
Published
2020-07-16
Published By
Ferrata Storti Foundation, Pavia, Italy
Print ISSN
0390-6078
Online ISSN
1592-8721
 

Article Usage

Online Views
177
PDF Downloads
59

Statistics from Altmetric.com

No Data
Navigate
For Authors
For Reviewers
For Advertisers
Education
Privacy
More
Copyright © 2020 by the Ferrata Storti Foundation | Web design ￫ | Development ￫
ISSN 0390-6078 print | ISSN 1592-8721 online